<?xml version="1.0" encoding="UTF-8"?><!--Transformation version 1.3--><legislativeDoc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://www.lexisnexis.com/xmlschemas/content/public/legislativedoc/1/" schemaVersion="1.0"><legislativeDocHead><citations><citeForThisResource citeDefinition="#7159#349#000054#     1#         3450#">Va. Code Ann. ยง 54.1-3450</citeForThisResource></citations><legislativeBodyInfo><jurisdiction><jurisSystem normalizedLongName="Virginia" normalizedShortName="VA"/></jurisdiction></legislativeBodyInfo></legislativeDocHead><legislativeDocBody><statute><level levelType="section"><anchor id="_54.1-3450"/><heading><desig>ยง 54.1-3450.</desig><title>Schedule III</title></heading><level levelType="paragraph"><bodyText><p>The controlled substances listed in this section are included in Schedule III:</p></bodyText><level levelType="paragraph"><anchor id="_1"/><heading><desig>1.</desig></heading><bodyText><p> Unless specifically exempted or listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:</p></bodyText><level levelType="paragraph"><bodyText><p><pre/>Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances which are specifically listed in other schedules;</p><p><pre/>Any compound, mixture or preparation containing amobarbital, secobarbital, or pentobarbital or any salt of amobarbital, secobarbital, or pentobarbital and one or more other active medicinal ingredients which are not listed in Schedules II through V;</p><p><pre/>Any suppository dosage form containing amobarbital, secobarbital, or pentobarbital or any salt of amobarbital, secobarbital, or pentobarbital and approved by the Food and Drug Administration for marketing only as a suppository;</p><p><pre/>Chlorhexadol;</p><p><pre/>Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the Federal Food, Drug, and Cosmetic Act <citation type="statute" normalizedCite="21 USC 355"><content><span normalizedCite="21 U.S.C. 355">(21 U.S.C. ยง 355);<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1828#123#000021#        355#"/></locatorKey></locator></span></content></citation></p><p><pre/>Embutramide;</p><p><pre/>Ketamine, its salts, isomers, and salts of isomers (some other names: [+-] -2-[2-chlorophenyl]-2-[methylamino]-cyclohexanone);</p><p><pre/>Lysergic acid;</p><p><pre/>Lysergic acid amide;</p><p><pre/>Methyprylon;</p><p><pre/>Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl) benxonitrile], including its salts, isomers, and salts of isomers;</p><p><pre/>Sulfondiethylmethane;</p><p><pre/>Sulfonethylmethane;</p><p><pre/>Sulfonmethane; and</p><p><pre/>Tiletamine-zolazepam combination product or any salt thereof.</p></bodyText></level></level><level levelType="paragraph"><anchor id="_2"/><heading><desig>2.</desig></heading><bodyText><p> Nalorphine.</p></bodyText></level><level levelType="paragraph"><anchor id="_3"/><heading><desig>3.</desig></heading><bodyText><p> Unless specifically excepted or unless listed in another schedule:</p></bodyText><level levelType="paragraph"><anchor id="_3_a"/><heading><desig>a.</desig></heading><bodyText><p> Any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts thereof:</p></bodyText><level levelType="paragraph"><bodyText><p><pre/>Buprenorphine.</p></bodyText></level></level><level levelType="paragraph"><anchor id="_3_b"/><heading><desig>b.</desig></heading><bodyText><p> Any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof:</p></bodyText><level levelType="paragraph"><bodyText><p><pre/>Not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;</p><p><pre/>Not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;</p><p><pre/>Not more than 1.8 grams of dihydrocodeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;</p><p><pre/>Not more than 300 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more ingredients in recognized therapeutic amounts;</p><p><pre/>Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;</p><p><pre/>Not more than 50 milligrams of morphine, or any of its salts, per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.</p></bodyText></level></level></level><level levelType="paragraph"><anchor id="_4"/><heading><desig>4.</desig></heading><bodyText><p> Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:</p></bodyText><level levelType="paragraph"><bodyText><p><pre/>Benzphetamine;</p><p><pre/>Chlorphentermine;</p><p><pre/>Clortermine;</p><p><pre/>Phendimetrazine.</p></bodyText></level></level><level levelType="paragraph"><anchor id="_5"/><heading><desig>5.</desig></heading><bodyText><p> The Board may except by regulation any compound, mixture, or preparation containing any stimulation or depressant substance listed in subsection A from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a stimulant or depressant effect on the central nervous system.</p></bodyText></level><level levelType="paragraph"><anchor id="_6"/><heading><desig>6.</desig></heading><bodyText><p> Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts of isomers is possible within the specific chemical designation:</p></bodyText><level levelType="paragraph"><bodyText><p><pre/>Anabolic steroids, including, but not limited to:</p></bodyText><level levelType="paragraph"><bodyText><p><pre/>3beta,17-dihydroxy-5a-androstane;</p><p><pre/>3alpha,17beta-dihydroxy-5a-androstane;</p><p><pre/>5alpha-androstan-3,17-dione;</p><p><pre/>1-androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1-ene);</p><p><pre/>1-androstenediol (3alpha,17beta-dihydroxy-5alpha-androst-1-ene);</p><p><pre/>4-androstenediol (3beta,17beta-dihydroxy-androst-4-ene);</p><p><pre/>5-androstenediol (3beta,17beta-dihydroxy-androst-5-ene);</p><p><pre/>1-androstenedione ([5alpha]-androst-1-en-3,17-dione);</p><p><pre/>4-androstenedione (androst-4-en-3,17-dione);</p><p><pre/>5-androstenedione (androst-5-en-3,17-dione);</p><p><pre/>Bolasterone (7alpha,17alpha-dimenthyl-17beta-hydroxyandrost-4-en-3-one);</p><p><pre/>Boldenone (Dehydrotestosterone)(17beta-hydroxyandrost-1,4,-diene-3-one);</p><p><pre/>Boldione (androsta-1, 4-diene-3, 17-dione);</p><p><pre/>Calusterone (7beta,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);</p><p><pre/>Clostebol (4-Chlorotestosterone)(Chlorotestosterone)(4-chloro-17beta-hydr oxyandrost-4-en-3-one);</p><p><pre/>Dehydrochloromethyltestosterone (4-chloro-17beta-hydroxy-17alpha-methyl-androst-1,4-dien-3-one) ;</p><p><pre/>Delta1-dihydrotestosterone (1-testosterone) (17beta-hydroxy-5alpha-androst-1-en-3-one);</p><p><pre/>Desoxymethyltestosterone (madol) (17alpha-methyl-5alpha-androst-2-en-17beta-ol);</p><p><pre/>Dromostanolone (Drostanolone) (17beta-hydroxy-2alpha-methyl-5alpha-androstan-3- one);</p><p><pre/>Ethylestrenol (17alpha-ethyl-17beta-hydroxyestr-4-ene);</p><p><pre/>Fluoxymesterone (9-fluoro-17alpha-methyl-11beta,17beta-dihydroxyandrost-4-en-3- one);</p><p><pre/>Formyldienolone (Formebolone) (2-formyl-17alpha-methyl-11alpha,17beta-dihydroxya ndrost-1,4-dien- 3-one);</p><p><pre/>Furazabol (17alpha-methyl-17beta-hydroxyandrostano[2,3-c]-furazan);</p><p><pre/>13-beta-ethyl-17alpha-hydroxygon-4-en-3-one;</p><p><pre/>4-hydroxytestosterone (4,17beta-dihydroxy-androst-4-en-3-one);</p><p><pre/>4-hydroxy-19-nortestosterone (4,17beta-dihydroxy-estr-4-en-3-one);</p><p><pre/>Mestanolone (17alpha-methyl-17beta-hydroxy-5-androstan-3-one);</p><p><pre/>Mesterolone (1alpha-methyl-17beta-hydroxy-[5alpha]-androstan-3-one);</p><p><pre/>Methandriol (methylandrostenediol) (17alpha-methyl-3beta,17beta-dihydroxyandrost-5-ene);</p><p><pre/>Methandrostenolone (Methandienone) (Dehydromethyltestosterone) (17alpha-methyl-17beta-hydroxyandrost-1,4-dien-3-one);</p><p><pre/>Methasterone (2alpha,17alpha-dimethyl-5alpha-androstan-17beta-ol-3-one);</p><p><pre/>Methenolone (1-methyl-17beta-hydroxy-5alpha-androst-1-en-3-one);</p><p><pre/>17alpha-methyl-3beta,17beta-dihydroxy-5a-androstane;</p><p><pre/>17alpha-methyl-3alpha,17beta-dihydroxy-5a-androstane;</p><p><pre/>17alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene);</p><p><pre/>17alpha-methyl-4-hydroxynandrolone (17alpha-methyl-4-hydroxy-17beta-hydroxyestr-4-en-3-one);</p><p><pre/>Methyldienolone (17alpha-methyl-17beta-hydroxyestra-4,9(10)-dien-3-one);</p><p><pre/>Methyltrienolone (17alpha-methyl-17beta-hydroxyestra-4,9-11-trien-3-one);</p><p><pre/>17-Methyltestosterone (Methyltestosterone)(17alpha-methyl-17beta-hydroxyandrost-4-en- 3-one);</p><p><pre/>Mibolerone (7alpha,17alpha-dimethyl-17beta-hydroxyestr-4-en-3-one);</p><p><pre/>17alpha-methyl-delta1-dihydrotestosterone (17beta-hydroxy-17alpha-methyl-5alpha-androst-1-en-3-one)(17-al pha-methyl-1-testosterone);</p><p><pre/>Nandrolone (19-Nortestosterone)(17beta-hydroxyestr-4-en-3-one);</p><p><pre/>19-nor-4,9(10)-androstadienedione(estra-4,9(10)-diene-3,17-dione);</p><p><pre/>19-nor-4-androstenediol (3beta,17beta-dihydroxyestr-4-ene);</p><p><pre/>19-nor-4-androstenediol (3alpha,17beta-dihydroxyestr-4-ene);</p><p><pre/>19-nor-5-androstenediol (3beta,17beta-dihydroxyestr-5-ene);</p><p><pre/>19-nor-5-androstenediol (3alpha,17beta-dihydroxyestr-5-ene);</p><p><pre/>19-nor-4-androstenedione (estr-4-en-3,17-dione);</p><p><pre/>19-nor-5-androstenedione (estr-5-en-3,17-dione);</p><p><pre/>Norbolethone (13beta,17alpha-diethyl-17beta-hydroxygon-4-en-3-one);</p><p><pre/>Norclostebol (4-chloro-17beta-hydroxyestr-4-en-3-one);</p><p><pre/>Norethandrolone (17alpha-ethyl-17beta-hydroxyestr-4-en-3-one);</p><p><pre/>Normethandrolone (17alpha-methyl-17beta-hydroxyestr-4-en-3-one);</p><p><pre/>Oxandrolone (17alpha-methyl-17beta-hydroxy-2-oxa-[5alpha]-androstan-3-one);</p><p><pre/>Oxymesterone (Oxymestrone) (17alpha-methyl-4,17beta-dihydroxyandrost-4-en-3-one);</p><p><pre/>Oxymetholone (Anasterone) (17alpha-methyl-2-hydroxymethylene-17beta-hydroxy-[5alpha]-androsta n-3-one);</p><p><pre/>Prostanozol (17beta-hydroxy-5alpha-androstano[3,2-c]pyrazole);</p><p><pre/>Stanolone (4-Dihydrotestosterone) (Dihydrotestosterone) (17beta-hydroxy-androstan-3-one);</p><p><pre/>Stanozolol (Androstanazole) (17alpha-methyl-17beta-hydroxy-[5alpha]-androst-2-eno[3,2-c]-pyrazole);</p><p><pre/>Stenbolone (17beta-hydroxy-2-methyl-[5alpha]-androst-1-en-3-one);</p><p><pre/>Testolactone (1-Dehydrotestololactone) (13-hydroxy-3-oxo-13,17-secoandrosta-1 ,4-dien-17-oic acid lactone);</p><p><pre/>Testosterone (17beta-hydroxandrost-4-en-3-one);</p><p><pre/>Tetrahydrogestrinone (13beta,17alpha-diethyl-17beta-hydroxygon-4,9,11-trien-3-one);</p><p><pre/>Trenbolone (Trienbolone) (Trienolone) (17beta-hydroxyestr-4,9,11-trien-3-one); and</p><p><pre/>Any salt, ester, or ether of a drug or substance described or listed in this paragraph. However, such term does not include an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the United States Secretary of Health and Human Services for such administration. If any person prescribes, dispenses, or distributes any such steroid for human use, such person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this subsection.</p></bodyText></level></level></level><level levelType="paragraph"><anchor id="_7"/><heading><desig>7.</desig></heading><bodyText><p> Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the U.S. Food and Drug Administration.</p></bodyText></level></level><history><historyGroup groupType="history-citation"><historyItem><bodyText><p>1972, c. 798, ยง 54-524.84:8; 1976, c. 614; 1977, c. 302; 1979, c. 387; 1982, c. 505; 1988, cc. 283, 765; <citation normalizedCite="1992 VA CH 737"><content><span normalizedCite="1992 Va. Ch. 737">1992, c. 737<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#1992#000737#"/></locatorKey></locator></span></content></citation>; <citation normalizedCite="2000 VA CH 135"><content><span normalizedCite="2000 Va. Ch. 135">2000, cc. 135<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2000#000135#"/></locatorKey></locator></span></content></citation>, <citation normalizedCite="2000 VA CH 348"><content><span normalizedCite="2000 Va. Ch. 348">348<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2000#000348#"/></locatorKey></locator></span></content></citation>; <citation normalizedCite="2003 VA CH 640"><content><span normalizedCite="2003 Va. Ch. 640">2003, c. 640<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2003#000640#"/></locatorKey></locator></span></content></citation>; <citation normalizedCite="2005 VA CH 119"><content><span normalizedCite="2005 Va. Ch. 119">2005, c. 119<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2005#000119#"/></locatorKey></locator></span></content></citation>; <citation normalizedCite="2006 VA CH 346"><content><span normalizedCite="2006 Va. Ch. 346">2006, c. 346<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2006#000346#"/></locatorKey></locator></span></content></citation>; <citation normalizedCite="2007 VA CH 14"><content><span normalizedCite="2007 Va. Ch. 14">2007, c. 14<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2007#000014#"/></locatorKey></locator></span></content></citation>; <citation normalizedCite="2010 VA CH 423"><content><span normalizedCite="2010 Va. Ch. 423">2010, c. 423<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2010#000423#"/></locatorKey></locator></span></content></citation>; <citation normalizedCite="2013 VA CH 233"><content><span normalizedCite="2013 Va. Ch. 233">2013, c. 233<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2013#000233#"/></locatorKey></locator></span></content></citation>; <citation normalizedCite="2014 VA CH 74"><content><span normalizedCite="2014 Va. Ch. 74">2014, c. 74<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2014#000074#"/></locatorKey></locator></span></content></citation>; <citation normalizedCite="2015 VA CH 303"><content><span normalizedCite="2015 Va. Ch. 303">2015, c. 303<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2015#000303#"/></locatorKey></locator></span></content></citation>.</p></bodyText></historyItem></historyGroup></history></level></statute></legislativeDocBody><metadata><dc:metadata xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:identifier identifierScheme="PGUID">urn:contentItem:5K0Y-PTB0-004G-K2CR-00000-00</dc:identifier><dc:source sourceScheme="productContentSetIdentifier">10816</dc:source><dc:date dateType="last-updated">2016-06-15</dc:date></dc:metadata><publicationInfo><publicationName>CODE OF VIRGINIA </publicationName><copyright>Copyright ยฉ 2016  by Matthew Bender &amp; Company, Inc. a member of the LexisNexis Group. All rights reserved</copyright></publicationInfo><hierarchy><hierarchyLevel levelType="title"><heading><desig>TITLE 54.1.</desig><title>PROFESSIONS AND OCCUPATIONS</title></heading><hierarchyLevel levelType="subtitle"><heading><desig>SUBTITLE III.</desig><title>PROFESSIONS AND OCCUPATIONS REGULATED BY BOARDS WITHIN THE DEPARTMENT OF HEALTH PROFESSIONS</title></heading><hierarchyLevel levelType="chapter"><heading><desig>CHAPTER 34.</desig><title>DRUG CONTROL ACT</title></heading><hierarchyLevel levelType="article"><heading><desig>ARTICLE 5.</desig><title>STANDARDS AND SCHEDULES</title></heading></hierarchyLevel></hierarchyLevel></hierarchyLevel></hierarchyLevel></hierarchy><classification classificationScheme="legal"><classificationItem><className>Business &amp; Corporate Compliance</className><classCode>Z3VpZD11cm46dG9waWM6MUFEMUQ2QTA1OUZCNEE5RjkzNTA2RERFMUNEOTk1RTI7cGFyZW50Z3VpZD0</classCode><classificationItem><className>Federal Food, Drug &amp; Cosmetic Act</className><classCode>Z3VpZD11cm46dG9waWM6QUEyREUxRkZEQjNENEQxQkE5QzcwMEExMUE5NDA1QTc7cGFyZW50Z3VpZD11cm46dG9waWM6NkVDMzM4QkJENTg3NDQ0RDg3NTA5OEM3RkMyQTlENDI</classCode></classificationItem></classificationItem><classificationItem><className>Criminal Law &amp; Procedure</className><classCode>Z3VpZD11cm46dG9waWM6NEU0RkE1OUQwNUQwNDgxODhEODZCMjkzOTg3NThBNzk7cGFyZW50Z3VpZD0</classCode><classificationItem><className>Miscellaneous Drugs</className><classCode>Z3VpZD11cm46dG9waWM6NjRFNURBMTlGODZENEEyNzhFQkM1MDkwQjlCNjhGNjQ7cGFyZW50Z3VpZD11cm46dG9waWM6QzFGQ0JDRjQ1RTA3NEJFOEI3QkVEREEyRDlFNTVBRDg</classCode></classificationItem></classificationItem><classificationItem><className>Governments</className><classCode>Z3VpZD11cm46dG9waWM6MjdEQjE4OUJDMzQxNDNEMEI0RTI1QUFCMzJENjEwRTA7cGFyZW50Z3VpZD0</classCode><classificationItem><className>Federal Food, Drug &amp; Cosmetic Act</className><classCode>Z3VpZD11cm46dG9waWM6QUEyREUxRkZEQjNENEQxQkE5QzcwMEExMUE5NDA1QTc7cGFyZW50Z3VpZD11cm46dG9waWM6NkVDMzM4QkJENTg3NDQ0RDg3NTA5OEM3RkMyQTlENDI</classCode></classificationItem><classificationItem><className>General Overview</className><classCode>Z3VpZD11cm46dG9waWM6NUI4RTIzQUE4NEU4NEQ2N0IyQUUzOEZFMDkyRkEyRDY7cGFyZW50Z3VpZD11cm46dG9waWM6NkVDMzM4QkJENTg3NDQ0RDg3NTA5OEM3RkMyQTlENDI</classCode></classificationItem></classificationItem><classificationItem><className>Torts</className><classCode>Z3VpZD11cm46dG9waWM6MDAwOEM2NTEzQkVDNEI4NzlGMEZERUEyRjQwODM4Njg7cGFyZW50Z3VpZD0</classCode><classificationItem><className>General Overview</className><classCode>Z3VpZD11cm46dG9waWM6MkQwMTc0MUU5MzkxNEMwQzhEQkU0QjA2REQzQzNGMTc7cGFyZW50Z3VpZD11cm46dG9waWM6RjMzQjNFQ0U1MDdFNEQzMjg0MTA0MTY4MUZCQTZBM0U</classCode></classificationItem></classificationItem></classification><classificationGroup classificationScheme="indexing-terms"><classification classificationScheme="legal"><classificationItem><className>Business &amp; Corporate Compliance</className><classCode>Z3VpZD11cm46dG9waWM6MUFEMUQ2QTA1OUZCNEE5RjkzNTA2RERFMUNEOTk1RTI7cGFyZW50Z3VpZD0</classCode><classificationItem score="90"><className>Businesses &amp; Corporations</className><classCode>Z3VpZD11cm46dG9waWM6QjA4OEVGODBENzY4NDcxM0IyQzA1OTEwQzVDODRBOUE7cGFyZW50Z3VpZD11cm46dG9waWM6MUFEMUQ2QTA1OUZCNEE5RjkzNTA2RERFMUNEOTk1RTI</classCode></classificationItem></classificationItem></classification></classificationGroup></metadata></legislativeDoc>